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The Zn-ﬁnger domain of MdmX suppresses cancer progression
by promoting genome stability in p53-mutant cells
Z Matijasevic, A Krzywicka-Racka, G Sluder, J Gallant and SN Jones
The MDMX (MDM4) oncogene is ampliﬁed or overexpressed in a signiﬁcant percentage of human tumors. MDMX is thought to
function as an oncoprotein by binding p53 tumor suppressor protein to inhibit p53-mediated transcription, and by complexing
with MDM2 oncoprotein to promote MDM2-mediated degradation of p53. However, down-regulation or loss of functional MDMX
has also been observed in a variety of human tumors that are mutated for p53, often correlating with more aggressive cancers and
a worse patient prognosis. We have previously reported that endogenous levels of MdmX can suppress proliferation and promote
pseudo-bipolar mitosis in primary and tumor cells derived from p53-deﬁcient mice, and that MdmX-p53 double deﬁcient mice
succumb to spontaneously formed tumors more rapidly than p53-deﬁcient mice. These results suggest that the MdmX oncoprotein
may act as a tumor-suppressor in cancers with compromised p53 function. By using orthotopic transplantation and lung
colonization assays in mice we now establish a p53-independent anti-oncogenic role for MdmX in tumor progression. We also
demonstrate that the roles of MdmX in genome stability and in proliferation are two distinct functions encoded by the separate
MdmX protein domains. The central Zn-ﬁnger domain suppresses multipolar mitosis and chromosome loss, whereas the carboxy-
terminal RING domain suppresses proliferation of p53-deﬁcient cells. Furthermore, we determine that it is the maintenance of
genome stability that underlies MdmX role in suppression of tumorigenesis in hyperploid p53 mutant tumors. Our results offer
a rationale for the increased metastatic potential of p53 mutant human cancers with aberrant MdmX function and provide a caveat
for the application of anti-MdmX treatment of tumors with compromised p53 activity.
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INTRODUCTION
The p53 transcription factor regulates expression of wide variety
of genes involved in cellular response to stress, and mutation of
p53 gene is the most common genetic lesion in human cancers.
The level of p53 activity in a cell is tightly regulated by the MDM2
and MDMX (MDM4) oncoproteins. These MDM homologs bind to
the amino-terminal p53 transactivation domain and inhibit p53
regulation of heterologous gene expression. MDM2 and MDMX
heterodimerize to facilitate MDM2-mediated ubiquitination and
degradation of p53.1–3 MDM proteins are required to negatively
regulate p53 activity in mice during the early and mid-stages of
development, and embryonic lethality caused by MDM-deﬁciency
is rescued by concomitant p53 deletion.4–7 Mdm2 and MdmX also
play critical roles in peri-natal and adult mice by controlling p53
regulation of cell differentiation, the DNA damage response, tissue
homeostasis and aging.8
MDM2 and MDMX also regulate p53-mediated tumor
suppression. MDM gene ampliﬁcation and/or overexpression have
been observed in a variety of human cancers, including leukemia
and lymphoma, breast cancer, glioblastoma, soft tissue sarcoma,
osteosarcoma and retinoblastoma.9–11 As most tumors with
ampliﬁed copy numbers of MDM genes retain wild-type p53,10,12
the increased level of MDM2 or MDMX proteins is thought
to promote oncogenesis by inhibiting p53 activity in these
cells. Experiments involving Mdm2 or MdmX overexpression
in cells or mice also suggest that MDM oncoproteins may
have p53-independent roles in regulating cell growth and
tumorigenesis13–17 although the precise contributions of these
p53-independent, proto-oncogenic effects in human cancers
remains uncertain.
We have previously shown that mice co-deleted for both MdmX
and p53 succumb to spontaneous tumorigenesis faster than mice
deleted solely for p53,18 suggesting p53-independent anti-
oncogenic function for MdmX in mice. In contrast, deletion of
Mdm2 fails to alter the tumorigenic potential of mice lacking
functional p53.19 Down-regulation or loss of functional MDMX
protein has also been associated with more aggressive or
advanced osteosarcomas, soft tissue sarcomas, thyroid and
prostate carcinomas, and chronic myelogenous leukemia.20–24 In
addition, an alternatively spliced MDMX variant is often found in
high-grade glioblastomas, papillary thyroid carcinomas, soft tissue
sarcomas and osteosarcomas.20,21,24 In both human tumors20,25
and in mouse model with targeted MdmX internal deletion26 this
altered splicing reduces the level of full-length (FL) MdmX
transcript and generates a novel transcript encoding a severely
truncated, unstable MdmX protein. The increase in short to FL
transcript ratio in osteosarcomas correlates with reduced MDMX
protein levels, faster metastatic progression and greatly reduced
patient survival.20 Lower MDMX protein levels in many osteosar-
coma or breast cancer cell lines and in soft tissue sarcomas
correlate with compromised p53 function.20 Although it is likely
that p53-mutant tumor cells have lost the selective pressure to
maintain high levels of functional MDMX, it is unclear why loss of
functional MDMX in these cells correlates with a more aggressive
cancer.
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We previously observed that p53-deﬁcient mouse embryo
ﬁbroblasts (MEFs) and p53-deﬁcient mouse tumor cells proliferate
faster when MdmX is also deleted, and that MdmX/p53-double-
null cells have increased incidence of multipolar mitosis and
reduced cell ploidy compared with p53-null cells.18 These ﬁndings
suggest a p53-independent role for MdmX in suppression of
proliferation and in maintenance of genome stability in hyper-
ploid mouse cells. In the present study, we use human tumor cells
in mouse orthotopic transplantation and lung colonization assays
to explore the relevance of these p53-independent effects of
MdmX in tumorigenesis. We provide the evidence that MdmX
suppresses tumor progression and metastases in these mouse
models of human cancer. Furthermore, we ﬁnd the inhibition of
cell proliferation and maintenance of genome stability to be
separable MdmX functions encoded by different MdmX protein
domains. We demonstrate that the ability of MdmX Zn-ﬁnger
domain to suppress multipolar mitosis and large-scale ploidy
reduction in p53-mutant cells underlies the role of MdmX in tumor
suppression. We discuss the implications of our ﬁndings on cancer
treatment strategies and on current models of genome instability
and cancer progression.
RESULTS
MdmX slows cycling of p53-deﬁcient cells
MdmX/p53 double-null MEFs and primary epithelial tumor cells
from MdmX/p53 double-null mice proliferate faster than MEFs and
tumor cells solely deﬁcient for p53 (ref. 18 and Figure 1a).
Multipolar mitosis (Figure 1b) are more common in populations
of MdmX/p53-double-null than in p53-null cells (20% vs 10%,
respectively, of all mitotic cells). Therefore, it is possible that the
divisions that generate more than two daughter cells per division
might contribute to the increased proliferation rate of MdmX/p53-
null cells. We have previously demonstrated27 that polyploid cells
undergoing multipolar mitosis can indeed generate more than
two daughter cells but many of the resulting progeny dies during
one or two subsequent divisions. Time-lapse video microscopy
analyses now revealed that only 21% of all multipolar mitosis
results in multipolar division and 71% of such progeny died or
arrested during the 69 h of ﬁlming. A majority (79%) of multipolar
mitosis produced only two viable daughter cells (Figure 1c) that
underwent normal bipolar mitosis and continued to divide
in bipolar fashion until the end of ﬁlming. Gamma-tubulin/
4ʹ-6-diamidino-2-phenylindole–staining of cells in late multipolar
anaphase typically revealed an unequal distribution of genetic
material illustrated in Figure 1d. Therefore, it is unlikely that
multipolar mitosis and the generation of more than two daughter
cells per division accounts for faster proliferation rate of
MdmX/p53-null cells. We applied live imaging to determine the
duration of cell cycle at the single-cell level by measuring the
length of time from the onset of anaphase in mother cell to
the onset of anaphase in daughter cells (Figure 1e). The
results showed that the absence of MdmX in p53-deﬁcient cells
signiﬁcantly shortens cell cycle length (Figure 1f). MEFs (left panel)
or tumor cells (right panel) lacking both MdmX and p53 cycled 5 h
and 2.5 h faster, respectively, than their p53-deﬁcient counterparts
retaining MdmX. Thus, it is a more rapid cell cycle progression and
not a higher number of daughter cells per division that accounts
Figure 1. MdmX slows cycling of p53-deﬁcient cells. (a) Proliferation of p53-null mouse tumor cells bearing or lacking MdmX.
(b) Immunoﬂuorescence staining of mouse tumor cells illustrating bipolar (left panels) and tripolar (right panels) anaphase. Cells were
stained for alpha-tubulin (green) and for DNA (4ʹ-6-diamidino-2-phenylindole (DAPI), blue). (c) Images from time lapse video microscopy of
MdmX/p53-null tumor cells undergoing tripolar mitosis and generating two viable daughter cells. (d) Immunoﬂuorescence staining for
gamma-tubulin (red) and DNA (DAPI, blue) of MdmX/p53-null cell undergoing multipolar mitosis with uneven distribution of genetic material.
(e) Images from time lapse video microscopy illustrating measurements of cell cycle length. (f) Quantiﬁcation of cell cycle length in MEFs
(left panel) and mouse tumor cells (right panel). Error bars represent mean± s.e.m. from 50 to 100 cell divisions scored for each cell line
(**Po0.0001, unpaired t-test). Scale bars, 10 μm.
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for the faster proliferation rates of p53-deﬁcient cells co-deleted
for MdmX.
The primary sequence of MdmX contains four functional
domains: an amino-terminal p53 binding (p53-BD) domain,
a central acidic domain, a zinc-ﬁnger (ZnF) domain of unknown
function and a carboxy-terminal RING domain critical for the
interaction of MdmX with Mdm2. To characterize the ability of
MdmX to suppress cell proliferation and multipolar mitosis, we
utilized mouse MdmX expression constructs encoding either the
FL, or mutant MdmX lacking carboxy-terminal RING domain
(dRING), central zinc-ﬁnger domain (dZnF) or both (dZnF-dRING;
Figure 2a). These constructs were co-transfected along with a
puromycin drug selection marker into the epithelial tumor cells
derived from MdmX/p53-double knockout (DKO) mice, and pools
of puromycin-resistant stably transfected cells were recovered for
further analyses.
Quantitative PCR analyses showed that the levels of MdmX
messenger RNA (mRNA) in transfected cells (FL, 14.2 ± 5.7, dRING,
11.0 ± 5.8; dZnF, 13.3 ± 3.6; dZnF-dRING, 35.2 ± 4.5) are similar to
the endogenous MdmX levels in p53 null mouse tumor cells
(13.7 ± 4.5) and in wild-type MEFs (11.07 ± 4.6). Proliferation assays
revealed that exogenous FL MdmX and dZnF mutant suppress
proliferation of MdmX/p53-deﬁcient cells (Figure 2b). In contrast,
MdmX lacking either the RING domain or lacking both the ZnF
Figure 2. MdmX RING domain suppresses proliferation of p53-null cells. (a) Schematic representation of mouse MdmX protein domains and
deletion mutants used in this study. (b) Proliferation of MdmX/p53-double knockout (DKO) mouse tumor cells transduced with MdmX FL or
deletion mutants. Error bars represent mean± s.d. from two to three independent experiments. (c) Cell cycle length of MdmX-transduced DKO
cells measured by time lapse video microscopy. Error bars represent mean± s.e.m. from 50 to 100 cell divisions scored for each cell line.
(d) Proliferation of transduced MdmX/Mdm2/p53-triple knockout (TKO) tumor cells. Error bars represent mean± s.d. from three to ﬁve
independent experiments. (e) Cell cycle length of MdmX-transduced TKO cells measured by time lapse microscopy. At least 100 cell divisions
were scored for each genotype. P-values relative to Mock control: **Po0.001, unpaired t-test.
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and RING domain failed to alter the proliferation of the double-
null cells. These results indicate that the RING domain of MdmX
encodes an anti-proliferative function. The role of the MdmX RING
domain in suppressing cell proliferation was conﬁrmed at the
single-cell level by video microscopy (Figure 2c). The presence of
MdmX RING domain, but not the central ZnF domain, correlates
with an ~ 2 h increase in cell cycle duration of p53-null cells.
Since MdmX interacts with Mdm2 and forms heterodimer
through its RING domain, we explored whether the p53-
independent effect of RING domain on cell proliferation requires
Mdm2. Tumor cells derived from Mdm2/MdmX/p53-triple
deﬁcient (TKO) mice were transduced with FL or MdmX deletion
constructs (relative MdmX mRNA levels: Mock, 1.0; FL, 6.6 ± 3.6;
dRING, 12.1 ± 7.0; dZnF, 23.5 ± 2.8; dZnF-dRING, 7.4 ± 2.3). Cell
proliferation assay (Figure 2d) reveal that MdmX with intact RING
domain suppresses proliferation of TKO cells. Analysis by video
microscopy conﬁrmed that the presence of RING domain
prolonged the cell cycling time from 11.5 h (Mock) to 12.3 h (FL)
or 12.8 h (dZnF) in TKO cells (Figure 2e). These results demonstrate
that the ability of MdmX to suppress proliferation of p53-deﬁcient
cells does not require functional Mdm2.
Zn-Finger domain of MdmX maintains genome stability in
mouse cells
We have reported that MdmX inhibits multipolar mitosis and
chromosome loss in hyperploid p53-deﬁcient cells.18 To identify
the domain(s) in MdmX protein responsible for promoting
genome stability, we analyzed the DNA content and chromosome
number of mouse DKO tumor cells transduced with MdmX
expression constructs. Propidium iodide staining and metaphase
spread analysis indicate that the expression of FL MdmX in
DKO cells increased DNA content and chromosome numbers to
the levels seen in tumor cells from p53-null mice retaining
endogenous MdmX (Figures 3a and b). This MdmX-mediated
increase in ploidy of DKO cells does not require the RING domain
(see Figure 3a and b, FL and dRING panels), but it does require ZnF
domain of MdmX (see Figure 3a and b, dZnF-dRING and dZnF
panels). Metaphase spread analyses summarized in Figure 3c
show that nearly the entire population of DKO cells with intact ZnF
domain contained more than 60 chromosomes per cell, while the
deletion of ZnF domain abolished this increase in chromosome
number.
We have proposed that genome instability in hyperploid
p53-deﬁcient cells lacking MdmX arises from aberrant chromo-
some segregation and loss during multipolar mitosis, an event
that occurs much more frequently in p53-null cells that also
lack MdmX.18 We therefore expect that the suppression of
chromosome loss by the Zn-ﬁnger domain may be linked to the
suppression of multipolar mitosis. The immunoﬂuorescence
analyses of spindle formation in DKO cells (Figure 3d) showed
that the expression of MdmX with intact ZnF domain reduced the
frequency of multipolar spindles by 50%. In contrast, expression of
MdmX lacking ZnF domain failed to decrease the incidence of
multipolar mitotic events. In Figure 3e, examples of normal bipolar
mitosis (left panel), multipolar mitosis represented by tri-polar
event (middle panel) and pseudo-bipolar mitosis with centro-
somes clustered around two opposite poles (right panel) are
shown. These results reveal that the ability of MdmX to prevent
chromosome loss and to suppress multipolar mitosis both require
the MdmX Zn-ﬁnger domain. To conﬁrm that MdmX function in
genome stability does not require Mdm2, the experiments
were repeated using the TKO tumor cells transduced with the
MdmX expression constructs. The results of chromosome analyses
(Figure 3f) and mitotic spindle analyses (Figure 3g) conﬁrmed that
Mdm2 is not required for MdmX to regulate genome stability.
The Zn-ﬁnger domain of MdmX maintains genome stability in
p53-deﬁcient human cells
To determine if MdmX has a p53-independent role in regulating
genome stability in human cells, we utilized MB157 breast tumor
cells that bear a truncating deletion in TP53 gene28 transduced
with MdmX expression constructs. Propidium iodide staining and
metaphase spread analyses revealed that the presence of either FL
or mutant MdmX lacking the RING domain increased DNA content
(Figure 4a) and chromosome number (Figure 4b) relative to the
Mock control or to cells with MdmX lacking Zn-ﬁnger domain.
Evaluating the number of cells with genome exceeding a triploid
chromosome content substantiated a role for MdmX ZnF domain
in promoting genome stability in p53-null human breast cancer
cells (Figure 4c).
To determine if the MdmX ZnF domain regulates spindle
polarity in human tumor cells, we performed immunoﬂuorescence
staining and analyzed spindle formation. Population of MB157
cells displayed high rate of multipolar mitosis and supernumerary
centrosomes, facilitating measurements of pseudo-bipolar mitotic
events. Formation of pseudo-bipolar spindles increased three-fold
when FL MdmX was expressed (Figure 4d) and this increase
correlated with the reduced number of multipolar mitotic
evens (Figure 4e). As in mouse cells, in MB157 human cells
MdmX-mediated suppression of chromosome loss correlates with
the suppression of multipolar mitosis and they both require intact
ZnF domain.
MdmX Zn-ﬁnger domain suppresses tumor growth
To determine if ZnF-dependent abilities of MdmX to suppress
multipolar mitosis and chromosomal loss can impact tumor
progression, we employed MB231 cells, a p53-mutant human
breast cancer cell line frequently used in orthotopic tumor
transplantation studies transduced with MdmX constructs.
Exogenous mouse MdmX mRNA levels in transduced cells
determined by quantitative PCR analyses normalized to Mock
are: FL, 8.2 ± 1.8; dRING, 16.4 ± 4.0; and dZnF, 15.4 ± 7.2. These
values are in the same range as the endogenous human MdmX
level (15.2 ± 5.3) measured in the same cells. We ﬁrst conﬁrmed
that MdmX also inhibits chromosome loss (Figure 5a) and
multipolar spindle formation (Figure 5b) in these cells only when
Zn-ﬁnger domain is intact.
For in vivo experiment, cells were transplanted into the
mammary fat pad of immune-compromised NSG (NOD-scid IL2ry
null) mice and tumors were harvested and measured 16 days later.
Tumors developed in all animals, but were much smaller in mice
implanted with MdmX-FL and MdmX-dRING-containing cells than
in mice with mock-control or MdmX-dZnF cells (Figure 5c). The
analysis of tumor size conﬁrmed the suppressive effect of the ZnF
domain on tumor progression (Figure 5d). Following tumor
dissection, cells were isolated and cultured for the spindle
analyses. Immunoﬂuorescence staining conﬁrmed that the sup-
pression of tumor growth with cells expressing intact Zn-ﬁnger
domain correlates with a reduction in number of multipolar
spindles before and after transplantation (Figure 5e).
MdmX suppresses metastatic potential of human cancer cells
To investigate the effect of MdmX on metastatic potential of
MB231 cells, we utilized whole-body in vivo bioluminescence
imaging and a dual reporter gene system. Mock-control cells or
cells transduced with MdmX-FL or MdmX-dZnF constructs were
infected with retrovirus encoding a FUW-M-cherry-Luciferase
reporter gene and sorted for M-cherry positive expression by
FACS. Robust expression of M-cherry was conﬁrmed by ﬂuores-
cence microscopy. Cells were injected into the tail-vein of NSG
mice, and lung colonization by MB231 cells was monitored over
time by whole-body imaging for luciferase activity. Representative
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images of bioluminescence signal at various time points are
shown in Figure 5F. The intensity of photon ﬂux in the lungs of
mice at different time intervals was normalized to the intensity on
day 1 (Figure 5g). The signal intensity increased over time in all
experimental animals injected with the reporter-bearing cells.
However, the colonization and growth of MB231 cells in the lungs
of mice were much slower when the injected cells expressed
MdmX with intact ZnF domain. Thus, the ability of MdmX to
inhibit both tumor progression and metastatic lung colonization
by human tumor cells in mice correlates with the presence of the
MdmX-central Zn ﬁnger domain. The deletion of Zn-ﬁnger domain
does not affect proliferation of MdmX-transduced MB231 cells
in vitro (Figure 5h) suggesting that the proliferation rate itself does
not underlay the differences in tumorigenic potential observed
in vivo.
DISCUSSION
MDMX is frequently ampliﬁed and overexpressed in human
cancers, and experiments utilizing human cells and genetically
altered mice have established that the oncogenic potential of
MdmX is largely due to its ability to inhibit the p53 tumor
suppressor. However, our lab has previously noted the existence
of p53-independent roles for MdmX in suppressing cell prolifera-
tion and in maintaining genome stability18,29 suggesting that
MdmX may have both oncogenic activity (via p53 inhibition) and
anti-oncogenic capabilities (in tumors mutated for p53). Here,
we establish that the carboxy-terminal RING domain of MdmX
prolongs the duration of cell cycle in p53-deﬁcient cells,
thereby suppressing cell proliferation. We also determine that
MdmX-mediated suppression of multipolar mitosis correlates with
increased genome stability in hyperploid mouse and human
Figure 3. Zn-ﬁnger domain of MdmX suppresses genome instability in mouse tumor cells. (a) DNA content of MdmX/p53-double knockout
(DKO) mouse tumor cells transduced with MdmX FL or deletion mutants determined by propidium iodide staining. DNA content of
experimental cells (red histograms) was superimposed over the DNA content of parental non-transduced MdmX/p53-null cells (blue
histograms). (b) Metaphase spread analysis for chromosome number per cell (in indicated ranges) in MdmX-transduced DKO cells. The results
are from representative experiment with at least 50 metaphase cells scored per cell line. (c) Summary of chromosome analyses showing cell
fraction with larger than triploid genome in population of transduced DKO cells. Error bars represent mean± s.d. from two to four
independent experiments with more than 50 metaphase cells scored per cell line per experiment. (d) Frequency of multipolar spindles as a
percent of total mitotic events in the populations of MdmX-transduced DKO cells. More than 200 mitotic spindles were scored per
experiment. Error bars represent mean± s.d. from three independent experiments. (e) Representative imunoﬂuorescence images of DKO cells
illustrating mitotic spindle organization. Cells were stained for alpha-tubulin (green), gamma-tubulin (red) and DNA (4ʹ-6-diamidino-2-
phenylindole, blue). Scale bar, 10 μm. (f) Chromosome analyses showing cell fraction with larger than triploid genome in population of
MdmX-transduced MdmX/Mdm2/p53-triple knockout (TKO) mouse tumor cells. Error bars represent mean± s.d. from two independent
experiments with at least 50 metaphases scored per cell line per experiment. (g) Frequency of multipolar spindles expressed as a percent of
total mitotic events in the populations of transduced TKO cells. Error bars represent mean± s.d. from two to three independent experiments.
P-values relative to Mock control: **Po0.005; *P from 0.005 to 0.05, unpaired t-test.
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tumor cells. This p53-independent function of MdmX maps to the
central Zn-ﬁnger domain of the MdmX protein that matches the
consensus sequence for the Ran binding protein 2 (RanBP2) type
zinc ﬁngers (ScanProsite results, release 20.119 of 12 October
2015, score 9.077). The Zn-ﬁngers domain in RanBP2 nucleoporin
facilitates its binding to the small GTPase Ran protein30 which is
associated with nuclear envelop assembly and mitotic spindle
morphogenesis.31,32 It can be speculated that MdmX demon-
strates its centrosome clustering function as one of the down-
stream targets for Run in spindle formation. As such, MdmX might
counteract the centrosome clustering inhibitory activity of
previously identiﬁed Ran target, nuclear mitotic apparatus protein
(Nu-MA).33,34 Both MdmX and Mdm2 proteins have conserved
RanBP2 zinc ﬁnger-like consensus sequences. However, there is
only 43% identity in amino acid sequence in Zn-ﬁnger domain
between the two proteins that may account for the difference in
their role in p53-independent tumorigenesis.
Increased cell proliferation and chromosomal instability are
hallmarks of tumorigenesis. Since we determined that the
suppression of proliferation and genome instability by MdmX
are independently regulated, we were able to examine relative
contributions of these activities to MdmX-mediated suppression
of tumorigenesis. Utilizing standard orthotopic transplantation
assays to measure tumor growth, and lung colonization by in vivo
imaging to measure metastatic activity, we determined that
MdmX-mediated genome stabilization underlies the ability of
MdmX to reduce tumorigenic potential of cells mutated for p53.
Although we cannot formally exclude a role for MdmX-mediated
inhibition of cell proliferation in tumor progression, it is
noteworthy that exogenous MdmX fails to alter proliferative
capacity of MB231 cells in vitro, yet it clearly suppresses tumor
formation and metastasis in vivo. It suggests that the tumorigenic
potential of hyperploid, p53-mutant cells is not driven by a
proliferative advantage but rather by the genomic instability
imparted by loss of MdmX.
Computational quantiﬁcation of somatic DNA alterations
in human cancers reveals that tetraploidy generated by
whole-genome doubling events occurs frequently during
tumorigenesis.35 Furthermore, polyploidy associated with
increased genetic instability promotes aneuploidy and accelerated
tumorigenesis in human cancers.36,37 Pan-cancer analyses
of somatic copy number alteration revealed that the
whole-genome doubling occurred in 37% of cancers with average
estimated ploidy of 3.31, suggesting the large-scale genome
Figure 4. Zn-ﬁnger domain of MdmX suppresses genome instability in p53-deﬁcient human cells. (a) DNA content determined by propidium
iodide staining of human breast tumor MB157 cells transduced with MdmX FL or deletion mutants. DNA content of experimental cells (red
histograms) was superimposed over the DNA content of Mock control cells (blue histograms). (b) Metaphase spread analysis for chromosome
number per cell (in indicated ranges) in transduced MB157 human breast tumor cells. At least 50 metaphases were scored per cell line.
(c) Summary of chromosome analyses showing cell fraction with larger than triploid genome in population of transduced MB157 cells. Error
bars represent mean± s.d. from three to four experiments with at least 50 metaphase cells scored per experiment. (d) Frequency of pseudo-
bipolar mitosis expressed as a percent of total mitotic events in population of MdmX-transduced MB157 cells. Spindles with ampliﬁed
centrosomes clustered around the opposite pools (see Figure 3d, right panel) were scored as pseudo-bipolar mitosis. Results from ﬁve
experiments with more than 100 mitotic events per experiment are shown in Box-whiskers plots. (e) Frequency of multipolar spindles in the
populations of transduced MB157 cells. More than 200 mitotic spindles were scored per experiment. Error bars represent mean± s.d. from
average of ﬁve experiments for each cell line. P-values relative to Mock control: **Po0.005; *P from 0.005 to 0.05, unpaired t-test.
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loss being associated with whole-genome doubling.38 However,
experiments with long-term culturing of tetraploid cells deriving
from diploid cancer progenitors39 revealed that, on per chromo-
some basis, tetraploidization by itself does not trigger additional
instability. Dewhurst et al.39 suggest that a tetraploid genome
increases cell tolerance to segregation errors and aneuploidy.
In agreement with this, our data provide direct evidence that it is
not the presence of a large genome per se but rather the ability
of these hyperploids to tolerate a greater range of genetic
imbalances leading to the evolution of aggressive growth
characteristics. We propose that MdmX exercises its tumor
suppressive activity in hyperploid cells with compromised p53
by preventing multipolar mitosis and stabilizing the large genome
of these cells, thus preventing chromosome loss. Loss of MdmX
may trigger large-scale ploidy reductions (only tolerated in
polyploid cells), reducing the ploidy to near-diploid levels until a
new cycle of polyploidization occurs within the cell. Such a
scenario of non-synchronized ‘genomic breathing’ in populations
of tumor cells might easily contribute to tumor heterogeneity, and
is concordant with the model of parallel evolution of different
subclones within the same tumor.40,41 Interestingly, overexpres-
sion of MdmX was recently shown to impair DNA damage
response and promote chromosome and chromatid breaks in
mouse embryo ﬁbroblasts in vitro.42 In contrast to those
aberrations that occur at the level of individual chromosome(s),
the genomic instability imparted by the loss of MdmX that we
refer to represents the large-scale genome loss restricted to the
polyploid cells that can lead to aneuploidy and tumorigenesis.
Figure 5. The Zn-ﬁnger domain of MdmX suppresses tumor growth and metastatic potential of human tumor cells. (a) Chromosome analyses
showing percent of cells with 490 chromosomes per cell in populations of human MB231 breast tumor cells transduced with MdmX FL or
deletion mutants. Error bars represent mean± s.d. from four to six mitotic spreads with at least 30 metaphase cells scored per cell line per
spread. (b) Frequency of multipolar spindles in populations of transduced MB231 cells. More than 200 mitotic events were scored per cell line
per experiment. Error bars represent mean± s.d. from four experiments. (c) Tumors formed after orthotopic transplantation of MB231 cells
into the mammary fat pad of nude mice. Tumors were harvested 16 days after transplantation. (d) Tumorigenic potential of transduced
MB231 cells transplanted into the fat pad of nude mice. Tumor size was calculated from equation: cm3=½ (W2 × L). The error bars represent
mean± s.d. of tumor size from 3 to 5 animals per each cell line. (e) Frequency of multipolar spindles in populations of cells cultured from
tumors harvested after transplantation of transduced MB231 cells into the mammary fat pad of nude mice. More than 500 mitotic events were
scored in population of cells deriving from each tumor. Error bars represent mean± s.d. from three to ﬁve tumors. (f) Representative
bioluminescence images of lung colonization in mice. MdmX-transduced MB231 cells infected with retroviral M-cherry-Luciferase reporter
were injected into the tail vein of nude mice. Lung colonization was assayed by bioluminescence imaging following intraperitoneal injection
of Luciferin. From left to right: control for auto-luminescence (cells without retrovirus); Mock (cells without MdmX); cells with FL MdmX; cells
with MdmX-dZnF mutant. (g) Metastatic potential of transduced MB231 cells expressing Luciferase reporter, injected into the tail vein of nude
mice (2.5 × 105 cells per animal, ﬁve animals per group). Luciferase activity was monitored over time using IVIS 100 imager. Intensity of photon
ﬂux within the region of interest from combined dorsal and ventral images of animals within the group was normalized to the intensity of
photon ﬂux on day 1. (h) Proliferation of MdmX-transduced MB321 cells used in experiments presented in a–g. P-values relative to Mock
control: **Po0.005; *P value from 0.05 to 0.005, unpaired t-test.
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These two quantitatively and mechanistically distinct MdmX-
mediated processes are not mutually exclusive and are likely
dependent on cellular context.
Our ﬁndings also suggest that genome stabilization by MdmX is
dependent upon the clustering of supernumerary centrosomes
and the promotion of pseudo-bipolar mitosis. Although centro-
some ampliﬁcation and clustering is not limited to cancer cells,43
it is believed that the centrosome clustering represents major
route for hyperploid cancer cells with ampliﬁed centrosomes to
escape multipolar mitosis and survive. Not surprisingly, identiﬁca-
tion and the inhibition of proteins involved in centrosome
clustering has become an attractive anticancer strategy.44,45
However, our experiments reveal that the majority of multipolar
mitosis generates viable daughter cells with increased levels of
aneuploidy and increased tumorigenic potential. Thus, our
ﬁndings offer a caveat to proposed cancer treatment strategies
that aim to promote multipolar mitosis. Furthermore, our data
indicate that the loss of MdmX in p53-mutant cells promotes
genome instability and cancer progression. As suggested by
recent studies demonstrating the failure of anti-MdmX strategy in
tumors expressing hypomorphic p53 mutant,46 our data indicate
that cancer treatments centered on MdmX inhibition should be
employed only in cases where tumor retains functional p53.
MATERIALS AND METHODS
Cells and cell culture
MEFs were isolated from 13.5-day-old embryos deriving from crosses
between MdmX+/− , p53+/− mice and MdmX+/− , p53− /− mice. Mouse
tumor cells were isolated from thymic tumors of MdmX− /− , p53− /−
mice or p53− /− mice and genotyped by PCR. The MdmX mouse model
used in this study previously obtained by gene-trapping47 does not
generate a detectable MdmX protein.6 Mouse cells were grown at 37 °C
with 5% CO2 in Dulbecco’s modiﬁed Eagle medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), penicillin and streptomycin.
Human tumor cell lines MDA-MB157 (obtained from ATCC) and MDA-
MB231 (gift from Dr. Jane Lian, UMASS Medical School) were established
from metastatic pleural effusion of human breast carcinomas.48
MB231 cells were grown at 37 °C with 5% CO2 in DMEM with penicillin,
streptomycin and 10% serum. For MB157 cells media was supplemented
with 15% serum. Cell line MB231 has missense mutation in exon 8 resulting
in mutant p53 protein49 and it is tumorigenic in nude mice.50 MB157 cells
are p53-deﬁcient due to the deletion in TP53 exon 4 resulting in the
absence of p53 protein.28 MB157 cells have hardly detectable levels of
MDMX protein.51 All cells were tested and were free of mycoplasma.
Plasmids
For the transfection experiments, murine MdmX complementary DNA
(cDNA) was placed under the transcriptional control of a conjugate
promoter bearing a cytomegaloviral enhancer and chicken-B actin
promoter sequences (pCAGGS). Construction of MdmX expression
plasmids with MdmX FL and MdmX deletion mutants MdmX-dRING
(amino acids 1–444), and MdmX-dZnF-dRING (amino acids 1–300) was
described previously.52 Those plasmids were generous gift from Steven J.
Berberich (Wright State University). Deletion mutant MdmX-dZnF
(d304-323) was generated from the wild-type MdmX cDNA by site-
directed mutagenesis and conﬁrmed by DNA sequencing (GenScript,
Piscataway NJ, USA).
Culturing cells from tumors
Following tumor dissection, tumors were minced in high glucose DMEM
supplemented with antibiotics and collagenase (2mg/ml), incubated at
37°C for 3 h with shaking, washed with PBS containing 5% FBS,
resuspended in DMEM with antibiotics and 2% FBS and plated on
collagen-coated plates. Cells were maintained in 2% FBS DMEM/F12
with antibiotics. Fibroblasts were removed by differential trypsinization.
Once cells reached growth crises, cells were fed with low glucose 10%
FBS DMEM.
Transfection of mouse and human cells
Cells were grown in DMEM with no antibiotics until 70–80% conﬂuent.
Linearized MdmX-expression constructs were co-transfected with PGK
promoter-puromycin drug selection marker using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) for transfection of mouse and MDA-MB231
human cells or XtremeGene-9 (Roche, Mannheim, Germany) for MDA-
MB157 human cells. Cells were split 24 h after transfection and selection
for puromycin resistance started 24 h later. Pools of puromycin-resistant
stably transfected clones were recovered for further analyses.
Quantitative real-time PCR
Total mRNA was isolated using RNeasy kit (Qiagen, Hilden, Germany). For
the ﬁrst-strand cDNA synthesis SuperScript III First-Strand Synthesis System
(Invitrogen) was used according to manufacturer’s instructions. Quantita-
tive PCR reaction was performed with SYBR Select Master Mix (Invitrogen)
using the ABI-9300 PCR machine. The MdmX mRNA data were normalized
to actin and the level in Mock control was assigned a value 1. Primers used
for quantitative PCR are as follows:
Mouse MdmX forward, 5ʹ-TCTCGCACAGGATCACACTATGGA-3ʹ;
Mouse MdmX reverse, 5ʹ-TCATCTGCTCTGGAGTCTCTGCAT-3ʹ;
Mouse Actin forward, 5ʹ-TCCTGTGGCATCCATGAAACT-3ʹ
Mouse Actin reverse, 5ʹ-GAAGCACTTGCGGTGCACGAT-3ʹ
Human MdmX forward, 5ʹ-GCAAGAAATTTAACTCTCCAAGCAA-3ʹ
Human mdmX reverse, 5ʹ-CTTTGAACAATCTGAATACCAATCCTT-3ʹ
Human Actin forward, 5ʹ-GGACTTCGAGCAAGAGATGG-3ʹ;
Human Actin reverse, 5ʹ-AGCACTGTGTTGGCGTACAG-3ʹ.
Time-lapse video microscopy
Cells were plated on coverslips 24 h before ﬁlming in DMEM media with
10% serum, penicillin, streptomycin and 12.5 mM Hepes. Coverslips with
attached cells were assembled into the sealed chambers53 and incubated
at 37 °C. Individual cells were observed under the Zeiss Universal or Leica
DMEXE microscope equipped with phase-contrast optics using × 10
objectives. Images were recorded with Orca ER, Orca100 (Hamamatsu,
Bridgewater, NJ, USA) Retiga EX and/or Retiga EXi cameras (Qimaging,
Surrey, BC, Canada), acquired every 3 minutes with C-imaging software
and exported as a QuickTime movies (100% of CinePak compression
mode). The duration of cell cycle was deﬁned as the time from anaphase
onset in mother cell manifested as the chromosome disjunction and/or
sudden start of cell elongation till the anaphase onset in daughter cells.
Immunoﬂuorescent microscopy
Cells were grown on glass coverslips, ﬁxed in methanol and stained
for microtubules with mouse monoclonal anti-α-tubulin (Sigma-Aldrich,
T5168) and for centrosomes with rabbit polyclonal anti-γ-tubulin
(Sigma-Aldrich, T5192) primary antibodies. Alexa488 and Alexa594
(Molecular Probes, A11001 and A11012) were used as secondary
antibodies. DNA was stained with 4ʹ-6-diamidino-2-phenylindole.
Immunoﬂuorescence images were recorded using a CCD camera attached
to an epiﬂuorescence Zeiss Axioplan 2 microscope (Zeiss, Thornwood, NY,
USA). Single images were acquired using Metamorph Imaging Software
(Universal Imaging, Downingtown, PA, USA).
Metaphase spreads and chromosome counting
Actively proliferating cells were incubated with Colcemid (Gibco;
0.02 μg/ml media) for 90 min, harvested and incubated in hypotonic
solution (0.075 M KCl) for 15 min at 37 °C and ﬁxed with methanol-acetic
acid. Drops of cell suspension were placed on microscope slides, dried,
4ʹ-6-diamidino-2-phenylindole stained and analyzed by ﬂuorescent
microscopy.
Orthotopic transplantation studies
MDA-MB231 cells stably transduced with FL or MdmX deletion mutants
were resuspended in PBS with 30% Matrigel (BD Biosciences, San Jose, CA,
USA). Cells (4 × 106) in 200 μl were injected into the mammary fat pad of
4 weeks old NSG mice, ﬁve animals per group. Tumor growth was
monitored externally and animals were killed 16 days after injection.
Tumors were harvested and tumor volume was calculated: total volume=
½ (length x width2).54 All animal work in this manuscript was approved by
the Institutional Animal Care and Use Committee of UMMS.
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Viral transduction of tumor cells
MDA-MB231 cells stable transduced with FL or MdmX deletion mutants
in DMEM media without antibiotic with Polybrene (Sigma-Aldrich, St Louis,
MO, USA; 8 μg/ml), 60–70% conﬂuent, were infected with FUW based
retroviral vector encoding dual M-cherry-Luciferase reporter (gift from
Hong Zhang, UMMS). Cells were incubated at 37 °C for 48 h and the
expression of M-cherry was conﬁrmed by ﬂuorescent microscopy. Cells
were propagated, harvested with Accumax (Innovative Cell Technologies)
and resuspended in sorting buffer (PBS with 1mM EDTA; 25 mM HEPES; 1%
FBS and antibiotics) at 7 × 106 cells/ml. Cells were sorted for positive
M-cherry expression using FACSAria II cell sorter in Core Flow Cytometry
facility at UMMS and propagated under standard conditions.
In vivo bioluminescence imaging
For tail vein injection, cells were resuspended in PBS at 1 × 106 cells/ml.
Using a 26G needle, 200 μl of cells were injected into the tail vein of
8-week-old NSG mice, ﬁve animals per group. Immediately following
injection, animals were imaged for the luciferase activity at time zero.
D-Luciferin (Gold Biotechnology, St Louis, MO, USA; LUCK-500) was
dissolved in DPBS (15 mg/ml), ﬁlter-sterilized and injected intraperitoneally
(150 mg/kg body weight). Animals were anesthetized with isoﬂurane for
5 min and imaged from both dorsal and ventral position by Xenogen IVIS
100 Imaging System, Caliper Life Sciences in Optical Imaging Core Facility
at UMMS. Mice were monitored for luciferase activity every other day for
the ﬁrst week and then weekly for the rest of the experiment.
Bioluminescence images of upper dorsal region corresponding to the
lung position were quantiﬁed using Living Image 2.60.1 software. The
values for photon ﬂux were normalized to those obtained at day 1.
Statistical analysis
The two-sample two-sided unpaired t-test was used to compare the mean
between two experimental conditions with the signiﬁcance level 0.05 and
conﬁdence interval 95%. Number of samples and P-values for speciﬁc
group of experiments are provided in ﬁgure legends. The normality of data
were tested by the stem and leaf plot or by Kolmogorov–Smirnov test
(for time-lapse video microscopy data). For animal studies sample size was
estimated using Mead’s resource equation with the degrees of freedom
between 10 and 20. No blinding or randomization methods were used.
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